Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G7YS
|
|||
| Former ID |
DIB008725
|
|||
| Drug Name |
ONYX-015
|
|||
| Synonyms |
Dl1520; E1B-deleted adenovirus (cancer), ONYX
Click to Show/Hide
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 1 | [1] | |
| Company |
Onyx Pharmaceuticals Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00006106) ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. | |||
| REF 3 | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000 Nov 15;60(22):6359-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.